Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Grants Priority Review to Keppra for Use in Childhood Epilepsy

By Pharmaceutical Processing | February 17, 2005

ATLANTA, Feb. 17 — UCB Pharma, Inc. has been granted a priority review for the supplemental new drug application (sNDA) seeking approval of its leading anti-epilepsy drug (AED) Keppra&reg (levetiracetam) as add-on therapy in children and adolescents with partial seizures in the USA.Under a priority review, the Food and Drug Administration (FDA) sets a six month target for deciding whether to approve a new drug application, instead of the standard target of 10 months after the date the application is filed. A priority designation is intended for products that address unmet medical needs and, if approved, would be a significant improvement on products already on the market.

UCB Pharma, Inc. submitted the pediatric sNDA for Keppra&reg on 20 December 2004, requesting approval of Keppra&reg for the adjunctive treatment of partial seizures in children down to four years of age. Keppra&reg was first marketed in the year 2000 and is now the most prescribed second generation AED for adults with partial onset seizures in the USA. The introduction of Keppra for children, as early as Q3 2005 in the US and EU, will give even more patients the opportunity to receive this innovative medicine.

The application is based on recent pivotal trial results in 198 patients showing excellent efficacy and safety in children aged 4-16 years with refractory epilepsy. The children who took part in the study were taking one or two other AEDs at entry. Seven percent of children who took Keppra&reg became seizure free during the 14 week double-blind, placebo controlled treatment period, compared with 1% of those taking placebo. Responder rates – a 50% or greater reduction in seizures – were 45% on Keppra&reg treatment and 20% on placebo (p=0.0002).Dr. Tracy Glauser, Director Comprehensive Epilepsy Program, Cincinnati Children’s Hospital, and principal investigator of the study stressed the importance of early, aggressive treatment of childhood seizures to lesson the risk of injury to the child, maximize school performance, and thereby improve their quality of life.

“Keppra&reg was effective and well tolerated by the children in our study, many of whom had been on eight or nine different drugs before trying Keppra&reg,” he said.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE